Home Alzheimer’s Disease Comparison of Drugs in the Metastatic and Adjuvant Settings

Comparison of Drugs in the Metastatic and Adjuvant Settings

A study published in JAMA Network Open found that in non-small cell lung cancer (NSCLC), breast cancer, and colon cancer, only 34.8% of drugs endorsed in the metastatic setting are also endorsed in the adjuvant setting. 

Given the potential benefit of adjuvant therapy in these disease spaces, the researchers indicated that further investigation into additional adjuvant systemic therapy options is necessary. 

“This finding is likely associated with a multitude of factors, especially the higher burden of proof required for adjuvant therapies and a general lack of correlation between efficacy of a drug in advanced cancers and benefit in early disease,” the authors wrote. “Although there are a number of ongoing trials aimed at elucidating additional agents for adjuvant use, there is still a high percentage of drugs that have yet to be studied, suggesting possible future…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments